Interpace Diagnostics leverages the latest technology to develop and commercialize novel molecular diagnostic tests. Our tests are designed to detect genetic alterations that are associated with indeterminate thyroid nodule risk stratification and are principally focused on early detection and identification of high potential progression to cancer.
ThyGenNEXT® is an oncogenic mutation panel that helps identify malignant thyroid nodules.
ThyGenXLearn MoreThyraMIR®v2 is a proprietary microRNA gene expression assay that helps to classify the risk of cancer in thyroid nodules.
ThyraMIRLearn More